

Lixisenatide TAG summary recommendations July 2013

The enclosed policies represent DRAFT recommendations to CCGs. It is proposed that individual CCGs consider the summaries and policies enclosed within their relevant decision making groups and respond to the CCG with a decision regarding adoption/amendment of the policy – please use the attached form. Further advice on the contents of the draft policies can be sought from the contacts list at the end of the document.

Lixisenatide injection (lyxumia)

Recommendation: Lixisenatide is recommended as a first line treatment option with NICE clinical guideline 87. Evidence shows it to be as effective as exenatide but better tolerated

Key points which were discussed include:

- Lixisenatide is a new glucagon-like peptide-1 mimetic for use in combination with basal insulin or oral antidiabetic drugs for treating type 2 diabetes in adults whose blood glucose is not adequately controlled on these treatments alone.
- It is administered by injection once daily.
- Place in therapy should be considered in line with NICE clinical guideline.
- There is evidence to show that it is as effective than exenatide but better tolerated relating to GI side effects, but there is no comparable data with liraglutide at present
- This is the cheapest GLP-1 agent on the market at present which will provide some savings to CCGs but will be dependent on uptake.
- Prescribing data shows that there is more liraglutide being prescribed compared to exenatide.
- No NICE guidance relating to this drug at present and none expected till 2014. SMC due to publish in September 2013.